Clinical InvestigationTools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure
Section snippets
Web-based application
To maximize accessibility, we developed a freely available Web-based tool that allows users to select modeling options and specify inputs in an integrated simulation model. The tool takes the form of a series of input pages (Table I). It includes 3 study design options: hypothetical scenario, parallel groups, and single cohort (Supplementary Figure A).
The hypothetical scenario design option allows the user to generate simulated outcomes for 2 patient groups with different clinical and treatment
CHIME
In CHIME, patients were hospitalized an average of 1.3 times, had 0.5 emergency department visits, and had 3.1 outpatient visits (Table II). By comparison, our model estimated 1.1 hospitalizations, 1.0 emergency department visits, and 13.9 outpatient visits. Mean total costs estimated using patient-level data from CHIME were similar to mean total costs estimated with the TEAM-HF model ($23,861 vs $23,621) when all levels of uncertainty were varied stochastically. When parameter estimates were
Discussion
The TEAM-HF Cost-Effectiveness Model provides a flexible tool for the research and clinical communities to evaluate the long-term cost-effectiveness of disease management programs in heart failure. In addition to facilitating formal cost-effectiveness analyses, the model can be used for budget planning, projecting hospitalization rates, and quantifying life expectancy for a cohort of patients over a period specified by the user. For example, the model could be used by health systems to predict
Disclosures
The University of Washington Center for Commercialization holds the copyright to the SHFM. Drs Schulman and Reed have made available online detailed listings of financial disclosures (www.dcri.duke.edu/research/coi.jsp).
Acknowledgements
Damon M. Seils, MA, Duke University, assisted with manuscript preparation.
References (28)
- et al.
Inpatient resource use and medical costs in the last year of life by mode of death in HF-ACTION
Am J Cardiol
(2012) - et al.
Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION
J Card Fail
(2013) - et al.
Economic effects of beta-blocker therapy in patients with heart failure
Am J Med
(2004) - et al.
Heart failure disease management programs: a cost-effectiveness analysis
Am Heart J
(2008) - et al.
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
Value Health
(2012) - et al.
Computer modeling of diabetes and its complications: a report on the fifth Mount Hood Challenge Meeting
Value Health
(2013) - et al.
Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs
Eur J Cardiovasc Nurs
(2015) - et al.
Cost-effectiveness of telephonic disease management in heart failure
Am J Manag Care
(2008) - et al.
Long-term cost-effectiveness of disease management in systolic heart failure
Med Decis Making
(2009) - et al.
Introduction of the TEAM-HF Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions
Circ Cardiovasc Qual Outcomes
(2012)
The Seattle Heart Failure Model: prediction of survival in heart failure
Circulation
Risk prediction models for mortality in ambulatory patients with heart failure: a systematic review
Circ Heart Fail
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Lancet
Rosuvastatin in older patients with systolic heart failure
N Engl J Med
Cited by (6)
Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement
2016, International Journal of CardiologyCitation Excerpt :However, transitional care typically continues for at most 3-months after hospital discharge, which risks readmission if self-care is not mastered and/or comorbid conditions are not stabilised during that period. Although interventions for specific disease combinations have been tested (e.g., HF and diabetes) [64–67], clinical guidelines integrating the care of multiple conditions are rare. [68]. Other approaches such as interdisciplinary primary care [69] and interdisciplinary teams for nursing home residents [70] are in the early phases of testing.
Strategies for cost-effectiveness analysis of rehabilitation for older patients with acute heart failure
2022, Cost Effectiveness and Resource AllocationLong-term monitoring in primary care for chronic kidney disease and chronic heart failure: A multi-method research programme
2021, Programme Grants for Applied ResearchEvaluation of a heart failure telemonitoring program through a microsimulation model: Cost-utility analysis
2020, Journal of Medical Internet ResearchThe Language of Data Program: Use of Gaming to Promote Critical Appraisal Skills
2018, Worldviews on Evidence-Based Nursing
Mark A. Hlatky, MD, served as guest editor for this article.